Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **combination of escitalopram**, a selective serotonin reuptake inhibitor (SSRI), and **eszopiclone**, a non-benzodiazepine hypnotic agent. Escitalopram increases serotonin levels in the brain by inhibiting its reuptake, primarily used for major depressive disorder and generalized anxiety disorder. Eszopiclone is a GABA-A receptor positive allosteric modulator, used to treat insomnia by enhancing central nervous system inhibition to promote sleep. This combination is explored for patients with comorbid generalized anxiety disorder and insomnia, with studies showing that coadministration improves sleep, daytime functioning, anxiety, and mood compared to escitalopram monotherapy. The combination is generally well tolerated, though increased CNS depression (such as somnolence, dizziness, and confusion) may occur[1][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on escitalopram + eszopiclone.